| Cat.No. | Name | Information |
|---|---|---|
| M1806 | PD 0332991 HCL | PD-0332991 HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. |
| M1974 | Roscovitine (Seliciclib) | Roscovitine is a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. |
| M2112 | LY2835219 mesylate | LY2835219 mesylate is an orally available inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM, respectively. |
| M1807 | SCH727965 (dinaciclib) | SCH727965 (Dinaciclib) is a potent and selective CDK inhibitor with IC50 values of 1, 1, 3 and 4 nM for CDK2, CDK5, CDK1 and CDK9, respectively. |
| M3519 | PHA-848125 | PHA-848125 is a potent, ATP-competitive CDK inhibitor for CDK2 with IC50 of 45 nM. It is >3-fold more selective for CDK2 than CDK1, 2, 4, 5, and 7. |
| M5228 | THZ1 | THZ1 is a covalent CDK7 inhibitor which has the unprecedented ability to target a remote cysteine residue located outside of the canonical kinase domain, providing an unanticipated means of achieving selectivity for CDK7. |
| M1710 | Flavopiridol | Flavopiridol (Alvocidib) is a competitive broad-spectrum CDK inhibitor with IC50 of 30,170,100 nM against CDK1, CDK2 and CDK4, respectively. |
| M6167 | Palbociclib | Palbociclib is a highly specific inhibitor of Cdk4 (IC50=11 nM) and Cdk6 (IC50=16 nM), having no activity against a panel of 36 additional protein kinases. |
| M5305 | RO-3306 | RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with Ki of 20 nM, >15-fold selectivity against a diverse panel of human kinases. |
| M4889 | Ribociclib succinate (LEE011 succinate) | Ribociclib succinate (LEE011 succinate) is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. |
| M49513 | CDK8-IN-12 | CDK8-IN-12 is an orally active, potent CDK8 inhibitor with a Ki of 14 nM. |
| M49512 | CDK7-IN-20 | CDK7-IN-20 is a potent, selective and irreversible CDK7 (CDK) inhibitor with an IC50 value of 4 nM. |
| M49511 | 3-Methylthienyl-carbonyl-JNJ-7706621 | 3-Methylthienyl-carbonyl-JNJ-7706621 is a potent and selective inhibitor of cyclin-dependent kinase (CDK), with IC50s of 6.4 nM and 2 nM for CDK1/cyclin B and CDK2/cyclin A, respectively. |
| M49510 | 7BIO | 7BIO (7-Bromoindirubin-3-Oxime) is the derivate of indirubin. |
| M45378 | VS2-370 | VS2-370 is a compound that targets CDK9 for studies related to tumors and viral infections. |
| M45377 | Sunaciclib | Sunaciclib is a CDK9 inhibitor that can be used in studies related to hematologic tumors. |
| M45376 | PRT2527 | PRT2527 is a cell cycle protein-dependent kinase 9 (CDK9) inhibitor that can be used in studies related to tumors and immune system diseases. |
| M45135 | Dalpiciclib hydrochloride | Dalpiciclib hydrochloride is an orally active and highly selective CDK4/6 inhibitor with IC50 values of 12.4 nM and 9.9 nM, respectively.Dalpiciclib hydrochloride showed antitumor activity against breast cancer and esophageal squamous cell carcinoma. |
| M45109 | ETX-197 | ETX-197 is a potential best-in-class (BIC), orally active CDK2 inhibitor for tumor-related studies. |
| M44693 | 2,4,6-Trihydroxybenzoic acid | 2,4,6-Trihydroxybenzoic acid, the flavonoid metabolite, is a CDK inhibitor. 2,4,6-Trihydroxybenzoic acid can be used for the research of cancer. |
| M43408 | CP-07 | CP-07 is a potent and selective PROTACCDK9 degrader (DC50: 43 nM). |
| M43407 | BSJ-03-204 triTFA | BSJ-03-204 triTFA is a PROTAC connected by ligands for Cereblon and CDK. |
| M41446 | Culmerciclib maleate | Culmerciclib maleate is a cyclin dependent kinase (CDK) inhibitor, and has antineoplastic activity. |
| M41444 | CDK7-IN-21 | CDK7-IN-21 is a potent CDK7 inhibitor. |
| M41443 | CDK-IN-12 | CDK-IN-12 is a CDK Inhibitor. |
| M41442 | CDK9-IN-26 | CDK9-IN-26 is a CDK9 inhibitor (IC50=0.18 μM). |
| M41441 | CDK9-IN-27 | CDK9-IN-27 is a CDK9 inhibitor (IC50s: 0.424 μM). |
| M41440 | Tacaciclib | Tacaciclib is a CDK inhibitor, antineoplastic effect. |
| M41439 | CDK7-IN-22 | CDK7-IN-22 is an CDK7 inhibitor with antitumor activity. |
| M41438 | CDK2-IN-15 | CDK2-IN-15 is an inhibitor of CDK2 with an IC50 of 2.9 μM. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
